E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown where in the body the embolus developed. |
|
E.1.1.1 | Medical condition in easily understood language |
prevention of secondary stroke in pts with recent history of ESUS |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067167 |
E.1.2 | Term | Cerebellar embolism |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014498 |
E.1.2 | Term | Embolic stroke |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060839 |
E.1.2 | Term | Embolic cerebral infarction |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10074422 |
E.1.2 | Term | Brain stem embolism |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of dabigatran etexilate (110 mg b.i.d. or 150 mg b.i.d., with dosing according to age and renal function), to ASA (100 mg once daily) for the prevention of stroke recurrence in patients with embolic stroke of undetermined source. |
|
E.2.2 | Secondary objectives of the trial |
The trial will also characterize the safety of dabigatran etexilate in this setting. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Assay Validation and Biomarker
Protocol Date: 27-JUN-14
Protocol Version: final |
|
E.3 | Principal inclusion criteria |
- Age ≥ 60 years or: Age 18-59 years plus at least one of the following additional risk factors for stroke: a) Mild to moderate heart failure, i.e. NYHA Class ≤ 3 with left ventricular ejection fraction ≤ 40% as documented by e.g. echocardiogram, radionuclide or contrast angiogram in the last 6 months, b) Diabetes mellitus (either type 1 or type 2)
c) Hypertension requiring medical treatment with antihypertensive medication, d) Patent foramen ovale with no interventional occlusion planned, e) Prior stroke or TIA (before index stroke), f) CHA2DS2-VASc score ≥ 3
- Ischemic stroke with a brain lesion visualized by neuroimaging (either brain Computed Tomography (CT) or Magnetic Resonance Image (MRI)). The visualized stroke is a non-lacunar infarct , e.g. involving the cortex or >1.5 cm (>2.0 cm if measured on MRI diffusion-weighted images) in largest diameter if exclusively subcortical.Visualization by CT usually requires delayed imaging >24-48 hours after stroke onset.
- The index stroke must have occurred either up to 3 months before randomization (Modified Rankin Scale(mRS) ≤3 at randomization) or up to 6 months before randomization (mRS ≤3 at randomization) in selected patients that are ≥ 60 years plus at least one additional risk factor for recurrent
stroke
- Arterial imaging or cervical plus TCD ultrasonography does not show extra-cranial or intracranial atherosclerosis with ≥ 50% luminal stenosis in artery supplying the area of acute ischemia.
- As evidenced by cardiac monitoring for ≥ 20 hours with automated rhythm detection, there is absence of any clear or definite Episode of AF (within a 20 hour period, either as single episode or cumulative time of multiple episodes).
Further inclusion criteria apply. |
|
E.4 | Principal exclusion criteria |
- Modified Rankin Scale of >4 at time of randomization or inability to swallow medications.
- Major risk cardioembolic source of embolism such as: a) intracardiac thrombus as evidenced by transthoracic or transesophageal echocardiography, b) paroxysmal, persistent or permanent AF, c) atrial flutter, d) prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical), e) atrial myxoma, f) other cardiac tumors, g) moderate or severe mitral stenosis, h) recent (< 4weeks) MI, i) valvular vegetations, or j) infective endocarditis.
- Any indication that requires treatment with an anticoagulant as per Investigator`s judgment.
- History of AF (unless it was due to reversible causes such as hyperthyroidism or binge drinking, and has been permanently resolved).
- Other specific stroke etiology (i.e. cerebral arteritis or arterial dissection, migraine with aura/vasospasm, drug abuse).
- Renal impairment with estimated CrCl (as calculated by Cockcroft-Gault equation) <30mL/min at screening, or where Investigator expects CrCl is likely to drop below 30mL/min during the course of the study.
- Lacunar stroke. Lacunar infarcts of restricted size in the deep parts of the brain in the territories of small penetrating arteries. They are absent from the cerebral and cerebellar cortex. On brain CT and MR images they are <1.5 cm in largest Diameter or <2.0 cm if measured on MRI diffusion sequences. In several pathological studies, sites of predilection included the lenticular nucleus, thalamus, central white matter, internal capsule, centrum ovale, corpus callosum, basis pontis, and, rarely, the cerebellum, midbrain and medulla. Infarcts <1.5 cm in largest diameter, or <2.0 cm if measured on MRI diffusion sequences, in the dorsal or lateral areas of the brainstem, in the territory of circumferential, rather than deep penetrating, arteries are not lacunar infarcts (note: history of lacunar stroke is not exclusionary).
22. Any duration of atrial fibrillation
Further exclusion criteria apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first recurrent stroke (ischemic, hemorrhagic, or unspecified) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1: Time to first major bleed
2: Time to Ischemic Stroke
3: Composite endpoint of (time to) nonfatal stroke, nonfatal myocardial infarction (MI) and cardiovascular death
4: Time to Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke)
5: Time to All-cause death
6: Time to first intracranial hemorrhage
7: Time to life-threatening bleed
8: Fatal bleed
9: Time to any bleed (all severities)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1: up to 36 months
2: up to 36 months
3: up to 36 months
4: up to 36 months
5: up to 36 months
6: up to 36 months
7: up to 36 months
8: up to 36 months
9: up to 36 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 169 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Austria |
Belgium |
Brazil |
Canada |
Chile |
China |
Colombia |
Croatia |
Czech Republic |
European Union |
France |
Germany |
Hong Kong |
Hungary |
India |
Japan |
Korea, Republic of |
Mexico |
New Zealand |
Peru |
Poland |
Portugal |
Russian Federation |
Serbia |
Singapore |
Slovakia |
Slovenia |
Spain |
Sweden |
Switzerland |
Taiwan |
Thailand |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 12 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |